Optimer will update investors when it reports 4th quarter results on February 28, 2013.

3) What and approximately when is the next known catalyst?

Right now the market is focused on the growth trajectory of revenue from DIFICID and the next update will be on February 28, 2013.

The company also has an ongoing Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation,

For those of us that aren't doctors (like me) that means the prevention of CDAD in patients undergoing bone marrow transplants.

The ultimate goal of the ongoing trial is to expand DIFICID's label. The company plans an interim look during the 2nd half of 2013.

4) What is OPTR's quarterly cash burn?

Optimer does not give guidance on cash burn. However, it's President projected that the company would reach an operational breakeven point 3 years after the launch of DIFICID, giving Optimer a breakeven commitment of July 2014.

5) Does OPTR have an existing line of credit and if so how much can they draw against it?